Evidence from heterogeneous AAV cohorts suggests various predictors of relapse, such as serological (PR3-ANCA positivity or ANCA-levels rise) and clinical (GPA, better kidney function) features. The gene discussed is PRTN3; the disease is granulomatosis with polyangiitis.